ReviewiScience2020
Engineering the Extracellular Matrix to Model the Evolving Tumor Microenvironment.
Review in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis.iScience · 2026Article
- Designing the matrix: extracellular matrix-informed strategies for bioengineered cancer models.Frontiers in bioengineering and biotechnology · 2026Review
- Cancer-associated fibroblasts at the crossroads of tumor progression and therapy resistance: from heterogeneity to precision reprogramming.Journal of the Egyptian National Cancer Institute · 2025Review
- Scaffolds Mimicking the Tumor Microenvironment for In Vitro Malignancy Models.Biomimetics (Basel, Switzerland) · 2025Review
- Exploring cell dynamics and tumor microenvironments: a comprehensive review of decellularized extracellular matrix (dECM) scaffolds in breast and prostate cancer research.Research in pharmaceutical sciences · 2025Review
- Collagen fiber density observed in metastatic ovarian cancer promotes tumor cell adhesion.Acta biomaterialia · 2025Article
- Transformative insights in breast cancer: review of atomic force microscopy applications.Discover oncology · 2025Review
- Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Elastocapillary effects determine early matrix deformation by glioblastoma cell spheroids.APL bioengineering · 2024Article
- The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment.Science advances · 2024Article
- Mechanical Constraints in Tumor Guide Emergent Spatial Patterns of Glioblastoma Cancer Stem Cells.Mechanobiology in medicine · 2024Article
- Biofabrication methods for reconstructing extracellular matrix mimetics.Bioactive materials · 2024Review
- Contribution of the ELRs to the development of advancedFrontiers in bioengineering and biotechnology · 2024Review
- Biomaterial-basedCancer pathogenesis and therapy · 2023Review
- Biofabrication of Modular Spheroids as Tumor-Scale Microenvironments for Drug Screening.Advanced healthcare materials · 2023Article
- Biophysical cues of in vitro biomaterials-based artificial extracellular matrix guide cancer cell plasticity.Materials today. Bio · 2023Article
- Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling.In vitro models · 2023Review
- Challenges and Opportunities Associated With Drug Delivery for the Treatment of Solid Tumors.Oncology reviews · 2023Review
- A 3D-printed scaffold-based osteosarcoma model allows to investigate tumor phenotypes and pathogenesis in an in vitro bone-mimicking niche.Materials today. Bio · 2022Article
- Sponge-like Scaffolds for Colorectal Cancer 3D Models: Substrate-Driven Difference in Micro-Tumors Morphology.Biomimetics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Clinical evidence supports a role for the extracellular matrix (ECM) in cancer risk and prognosis across multiple tumor types, and numerous studies have demonstrated that individual ECM components impact key hallmarks of tumor progression (e.g., proliferation, migration, angiogenesis). However, the ECM is a complex network of fibrillar proteins, glycoproteins, and proteoglycans that undergoes dramatic changes in composition and organization during tumor development. In this review, we will highlight how engineering approaches can be used to examine the impact of changes in tissue architecture, ECM composition (i.e., identity and levels of individual ECM components), and cellular- and tissue-level mechanics on tumor progression. In addition, we will discuss recently developed methods to model the ECM that have not yet been applied to the study of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.